Pharma BD Deal Intelligence
Incyte adds subcutaneous delivery optionality to its lead mutCALR antibody
Full analysis, sources & comparables →Halozyme entered a global collaboration and license agreement with Incyte to evaluate additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms, using Halozyme's proprietary ENHANZE drug delivery technology. Halozyme receives an undisclosed upfront payment and is eligible for additional payments on achievement of agreed milestones. Incyte also secured an option to nominate up to two additional development targets using ENHANZE. Specific financial terms were not disclosed.
Myeloproliferative neoplasms driven by mutant calreticulin (mutCALR) include essential thrombocythemia and myelofibrosis. INCA033989 is a first-in-class monoclonal antibody targeting mutCALR; the collaboration applies Halozyme's ENHANZE recombinant hyaluronidase technology to enable subcutaneous formulations.
The global collaboration and licence applies Halozyme's ENHANZE recombinant hyaluronidase technology to subcutaneous formulations of INCA033989, Incyte's first-in-class mutCALR-targeted antibody for myeloproliferative neoplasms, and gives Incyte an option to nominate up to two further ENHANZE targets. Halozyme receives an undisclosed upfront and is eligible for milestone payments; no amounts were disclosed.
Incyte adds subcutaneous delivery optionality to its lead mutCALR antibody
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Incyte Corporation / Halozyme Therapeutics, Inc. (this deal) | 2026 | — | 60 |
| Incyte Corporation / MacroGenics, Inc. | 2017 | $900M | 69 |
| Incyte Corporation / Vega Therapeutics, Inc. | 2026 | $2.0B | 68 |
| Incyte Corporation / Merus N.V. | 2017 | $3.0B | 35 |
| Incyte Corporation / Genesis Molecular AI, Inc. | 2026 | $1.0B | — |
| Incyte Corporation / Escient Pharmaceuticals Inc. | 2024 | $750M | — |
| Incyte Corporation / Calithera Biosciences, Inc. | 2017 | $803M | — |
← Browse all deals · How we score deals
More: 2026 deals · Incyte Corporation deals